VBIO Pharma is a certified high-tech enterprise and a global leader in human and animal reproductive biological products (including IVF and fertility-related applications), founded in 2015. The company is backed by elite experts in protein bioproducts from MSD, Yale University, the University of California, Berkeley, the University of Washington and the University of Toronto. Boasting a team of over 200 employees, we specialize in the R&D, manufacturing and sales of API, pharmaceutical preparations, veterinary drugs, intimate-health and personal-care products. With a registered capital of RMB 65 million and a plant area of 100,000 square meters, VBIO holds more than 50 domestic and international patents, and has accumulated practical experience serving over 30 million pigs, cattle, sheep and aquatic animals. Headquartered in Guangzhou Economic and Technological Development Zone, the company is committed to delivering world-class innovative services, and has obtained qualifications and honors including National High-Tech Enterprise, Guangdong Provincial Specialized, Refined, Differential and Innovative Enterprise, and Guangzhou Innovative & Entrepreneurial Leading-Talent Enterprise.
The technical team of VBIO has years of proven experience in developing human biopharmaceutical products at home and abroad, covering fields such as IVF and embryo transfer. It has independently built a world-leading core technology platform for highly-glycosylated protein innovative drugs, incorporating key technologies including genetically-engineered recombinant protein and long-acting modification, as well as large-scale extraction and purification of native proteins. Its products feature distinct competitive strengths such as complete glycosylation profiles, high biological activity and low production costs. The technology platform has been successfully applied to the R&D and commercial launch of multiple innovative human and veterinary medicines. A number of Class-I new veterinary drugs have been developed, including the world’s first long-acting follitropin produced by mammalian cells, with multiple invention patents granted in China and the United States.
Targeting industry demands to resolve reproductive bottlenecks and improve breeding efficiency, VBIO has built a complete product portfolio for reproduction management covering the breeding sectors of pigs, cattle, sheep and aquatic species, with 22 production approvals granted. Flagship offerings include Weiyi Pei®, an innovative high-efficiency single-mating technology for sow reproduction, as well as world-first products such as long-acting follitropin for cattle and sheep embryo transfer. Validated by China’s top 30 livestock-breeding groups, VBIO’s products can substantially lift breeding efficiency, cut costs and boost profitability, generating considerable economic benefits for farming clients. At present, the company’s full-line products are marketed across multiple Chinese provinces and municipalities. It has served numerous industry leading enterprises including COFCO, Wens, Muyuan, Tianbang, CP Group and Mengniu. Ranking among the top 3 players in its niche market, VBIO is a well-established brand within the industry.